Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Net Margin (2016 - 2025)

Historic Net Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 9.32%.

  • Corcept Therapeutics' Net Margin fell 162500.0% to 9.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.12%, marking a year-over-year decrease of 82300.0%. This contributed to the annual value of 20.7% for FY2024, which is 11700.0% down from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Net Margin is 9.32%, which was down 162500.0% from 17.8% recorded in Q2 2025.
  • Corcept Therapeutics' Net Margin's 5-year high stood at 33.96% during Q3 2022, with a 5-year trough of 9.32% in Q3 2025.
  • Its 5-year average for Net Margin is 22.76%, with a median of 23.24% in 2023.
  • Per our database at Business Quant, Corcept Therapeutics' Net Margin crashed by -163900bps in 2022 and then soared by 69600bps in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Net Margin stood at 32.44% in 2021, then crashed by -51bps to 16.04% in 2022, then surged by 43bps to 23.0% in 2023, then fell by -27bps to 16.71% in 2024, then tumbled by -44bps to 9.32% in 2025.
  • Its last three reported values are 9.32% in Q3 2025, 17.8% for Q2 2025, and 12.9% during Q1 2025.